BIRC3 and B-cell chronic lymphocytic leukemia: Recent work showed that in addition to the loss-of-function mutations, patients with low BIRC3 mRNA expression have a more progressive course of disease due to an altered NF-κB pathway which is associated with increased dependency of CLL cells on the Bcl-2 rheostat, and enhanced sensitivity to Bcl-2 inhibition.